Development of novel immune combination therapy for interstitial pneumonia associated with connective tissue disease

2021 Fiscal Year Final Research Report

• Project/Area Number: 19K08623
• Research Category: Grant-in-Aid for Scientific Research (C)
• Allocation Type: Multi-year Fund
• Section: 一般
• Review Section: Basic Section 53030:Respiratory medicine-related
• Research Institution: Hamamatsu University School of Medicine
• Principal Investigator: Nakamura Yutaro 浜松医科大学, 医学部附属病院, 講師 (60436962)
• Co-Investigator(Kenkyū-buntansha): 須田 隆文 浜松医科大学, 医学部, 教授 (30291397)
• Project Period (FY): 2019-04-01 – 2022-03-31
• Keywords: 間質性肺炎 / 膠原病 / 樹状細胞

Outline of Final Research Achievements

We aimed to develop a novel therapeutic vaccine for the patients with interstitial pneumonia associated with connective tissue disease, suppressing local inflammation of the lung. We also analyzed the histological findings with human lung specimens from the patients with rheumatoid lung disease (RLD). Eventually we found that fibrotic components might be more important for the prognosis of RLD patients than inflammatory components.

Free Research Field

呼吸器内科学

Academic Significance and Societal Importance of the Research Achievements

我々は人の肺の外科的生検検体を用いた検討において，炎症性病態も重要であるが，より線維化病態が予後に与える影響が大きい可能性を示した．これらの結果より現状では，ほぼ炎症性病態のみを標的とした樹状細胞を用いた治療ワクチンの効果は限定的であり，さらに医学的効果のみならず臨床応用後の対費用効果の面からもその有用性は乏しいことが考慮された．以上から引き続き，人，マウスの検体を用いた検討をさらに進め，より効果的な膠原病に伴う間質性肺疾患の治療ターゲットを探索する研究を継続している．